Oxcarbazepine NDC 72888-460

NDC codes

FDA NDC Directory

Product NDC (as listed)72888-460Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72888-0460Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72888-460-01	72888046001	100 TABLET in 1 BOTTLE (72888-460-01)Marketed from May 20, 2025
72888-460-02	72888046002	500 TABLET in 1 BOTTLE (72888-460-02)Marketed from May 20, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxcarbazepine
Generic name (nonproprietary): oxcarbazepine
Active ingredients: Oxcarbazepine — 300 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Advagen Pharma Ltd.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207717
Marketing start: May 20, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 72888-460_49fe26b4-1dcb-832f-e063-6294a90a6195SPL ID 49fe26b4-1dcb-832f-e063-6294a90a6195SPL set ID ab4c1f36-82fa-40a2-a31a-227875d0f382RxCUI 312136, 312137, 312138UNII VZI5B1W380UPC 0372888461014, 0372888460017, 0372888462011, 0372888460024, 0372888462028, 0372888461021
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472888046001 followed by a unit qualifier and the quantity

Package 72888-0460-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 4, 2026.

Indications (excerpt from the label)

Oxcarbazepine tablets is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine tablets is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4-16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2-16 years

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207717

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207717
Product	Strength	Form · route	Labeler	Product NDC
Oxcarbazepine	Oxcarbazepine 150 mg/1	TabletOral	Advagen Pharma Ltd.	72888-462
Oxcarbazepine	Oxcarbazepine 600 mg/1	TabletOral	Advagen Pharma Ltd.	72888-461